

# A Quick Review of SGLT2 Inhibitor Empagliflozin in Clinical Practice

Zahra Tolou Ghamari\*

Department of Research and Technology, Isfahan University of Medical Sciences, Isfahan, Iran

## ABSTRACT

Empagliflozin or Jardiance could be prescribed in forms of immunotherapy or polypharmacy with metformin or insulin for patients with diabetes as an angiotensin converting enzyme inhibitor, angiotensin receptor blocker, Sodium Glucose Cotransporter Type 2 (SGLT2) inhibitor and albuminuria lowering agent. The aim of this review was to provide updated information associated with the clinical pharmacokinetics and pharmacotherapy of empagliflozin. This review was conducted according to published PRISMA guidelines. SGLT2 plays a crucial role in glucose transport and intraadrenal osmolality. In fact SGLT2 actively mediated 90% reabsorption of glucose by the kidneys. The over activation of SGLT2 in diabetic patients, leads to an increase in glucose and sodium reabsorption. Empagliflozin inhibits this cotransporter that leads to loss of glucose in the urine and a reduction in hyperglycemia. Similar to Glucagon-Like Peptide 1 (GLP-1) agonists, empagliflozin could cause reduction in albuminuria. The drug is orally active with a competitive binding to glucose. By oral administration the drug has a rapid absorption and metabolized by glucuronide conjugation. Excretion is through urine and feces. Pharmacotherapy used empagliflozin by reducing kidney disease progression's could improve conditions in patients with; diabetes (types 1 or 2), overweight and blood pressure. In addition in those with chronic kidney disease empagliflozin could improve serum mineral and bone markers. Further evidence-based pharmacotherapy studies recommended establishing the drug bioavailability, efficacy and side effects'.

**Keywords:** Glucuronide; Bioavailability; Empagliflozin; Pharmacotherapy

## INTRODUCTION

From May 2013, a medication that could be used with other drugs, regimented diet and exercise have got marketing approval in type 2 diabetes in which called empagliflozin or Jardiance. In combination with other classes of drugs it has potential for lowering glucose in type 2 diabetes. (Figure 1) shows the mechanism of action of empagliflozin as a potent inhibitor of Sodium Glucose Cotransporter 2 (SGLT2) [1]. Peak plasma concentration reported 1.3-3 hours after oral taken drug. Half-life ranged from 10.3-18.8 hours. Trough concentrations remain constant after day 6. Plasma binding protein is about 80%. [2,3] Oxidative stress was mentioned as the main contributor to diabetic kidney disease onset. In fact in the kidney, the proximal tubular cells require a high energy supply to reabsorb proteins, metabolites, ions, and water. Increased glucose level in urine and ROS enhance the activity of Sodium/Glucose Co-transporter Type 2 (SGLT2), which in turn exacerbates oxidative stress [4]. The

cardiovascular benefits of empagliflozin also were reported based on clinical studies in rats [5]. By glucose lowering effects and stimulating glycosuria excretion, the drug offers cardio protective effects [6]. In animal model and patients there is a report regarding a reduction in HbA1c upon chronic treatment with empagliflozin [7]. In prediabetes metabolic syndrome rats, SGLT2 inhibition reduces visceral adipocytes hypertrophy and ameliorates cardiac injury [8]. Empagliflozin inhibit weight gain by enhancing fat ingestion and decrease obesity induces inflammation and insulin resistance in white adipose tissue and liver [9]. In hypertensive heart failure rat model [10], the drug improved hemodynamics and reduce blood pressure [11]. For diabetic macro vascular disease and cognitive deterioration [12,13], empagliflozin could be considered as a potentially talented beneficial drug. Down-regulation of SGLT1, SGLT2 and GLUT1 expression could be an explanation for its properties [14]. Glomerular or tubular hypertrophy, focal segmental glomerulosclerosis or bulbous sclerosis, are the

**Correspondence to:** Zahra Tolou Ghamari, Department of Research and Technology, Isfahan University of Medical Sciences, Isfahan, Iran; E-mail: toloeghamari@pharm.mui.ac.ir

**Received:** 24-Jan-2022, Manuscript No. JPR-22-15953; **Editor assigned:** 26-Jan-2022, PreQC No. JPR-22-15953 (PQ); **Reviewed:** 09-Feb-2022, QC No. JPR-22-15953; **Revised:** 24-Mar-2022, Manuscript No. JPR-22-15953 (R); **Published:** 31-Mar-2022, DOI: 10.35248/JPR.22.6.127

**Citation:** Ghamari ZT (2022) A Quick Review of SGLT2 Inhibitor Empagliflozin in Clinical Practice. J Pharma Reports. 6:127

**Copyright:** ©2022 Ghamari ZT. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

histological changes of kidney in patients with obesity, that reactive oxygen species inhibitors and SGLT2 inhibitors and melatonin suggested to be used [15]. A recent report confirmed that the drug might slow the loss of kidney function and delay the estimated onset of projected end-stage kidney disease in those with type 2 diabetes and cardiovascular disease complicated nephritic range proteinuria [16]. With respect to the Reno protection for the treatment of Type 2 diabetes in those with a baseline eGFR of more than 60 ml/min/1.73 m<sup>2</sup>, HbA1C>7%, or young age (<65 years), empagliflozin could be suggested as the preferred choice of management [17]. The aim of this review was to provide updated information associated with the mechanism of action, clinical pharmacokinetics and pharmacotherapy of empagliflozin.




Figure 1: Mechanism of action of Empagliflozin.

## LITERATURE REVIEW

This review was conducted according to published PRISMA guidelines (Figure 2) [13]. The clinical question to guide the review was obviously defined following the structured PICOS framework. The PICOS question is individuals with empagliflozin and disease (Population), not intervention (Intervention) from the start of the study time period (Comparisons) efficacy and side effects (Outcomes) using existed published articles (Study design)? The electronic databases PubMed, Scopus, and Web of Science were systematically searched. Search strategies used selected subject headings and key words related to empagliflozin and disease combined with (“Pharmacokinetics” and “Efficacy” and “Side effects”). Reference lists of reviews and retrieved articles were checked to identify potentially relevant articles. Studies were eligible if they met the following predetermined selection criteria: 1) the study is population based. 2) Outcome measure was incidence and prevalence. The titles and abstracts of all manuscripts identified by the demands were individually studied for their suitability. Inconsistencies were considered and determined over agreement. The full text of all articles supposed actually appropriate. 40 relevant studies included review articles, clinical trials and case reports from the used references were evaluated.




Figure 2: Flow diagram of study selection for the systematic review.

## RESULTS

Table 1 shows pharmacokinetics properties, clinical and side effects of empagliflozin. The recommended guideline for patients with type 2 diabetes mellitus is based on initiating pharmacotherapy with empagliflozin an oral antidiabetic drug. Study showed that chronic kidney disease was associated with 303 urinary peptides that the most fragments mentioned as collagen types I, II and III, uromodulin, albumin and beta-2-microglobulin [18-20]. Pharmacotherapy used as empagliflozin could be a promising strategy for prevention and treatment of diabetic cardiomyopathy empagliflozin.

The prescription of empagliflozin is robust with regard to efficacy and safety. Poly pharmacy with metformin considers empagliflozin as a first line of pharmacotherapy regarding reduction in risk of cardiovascular disease, absence of weight gain and low risk of hypoglycemia. Associated improvement of overweight linked inflammation and insulin resistance, empagliflozin swelling energy spending and adipose tissue burning [21].

Improvement in indices of left ventricular diastolic cardiac dysfunction by regularizing the size and number of mitochondria is another mechanism of action in diabetic patients with cardiovascular disease as well.

[22] Moreover, due to hemodynamic properties that connected with reduction in intraglomerular pressure, empagliflozin could cause long-term protection in function of kidneys [23]. By raising serum uric acid empagliflozin could improve the metabolic disease that called hyperuricemia [24].

Regarding glucose tolerance in type 1 diabetes, animal study described an important advance with empagliflozin [25]. In population with type 2 diabetes, empagliflozin decreases aminotransferases [26].

**Table 1:** Empagliflozin: Pharmacokinetics properties, clinical use, side effects.

| Pharmacokinetics properties  |  |
|--|--|
| Tmax: 1-1.3 h, T1/2: 10.3-18.8, PB; 30%  |  |
| Polypharmacy with Valproate Concentration of Valproate   |  |
| Clinical use   | Side effects   |
| Type 2 Diabetes  | Urinary Tract Infections (UTIs)  |
| Weight and Blood Pressure  | Fungal Infections of the groin   |
| Cardiovascular Disease   | Joint pains  |
| Type 1 Diabetes  | Skin infection of the groin  |
| Contraindications: Allergic Reaction to Drug, End Stage Kidney Disease, Diabetic Keto Acidosis | Diabetic ketoacidosis with normal blood sugar<br>Contraindicate in those with significant kidney disease |

**Abbreviations:** Tmax: Time to reach Maximum Concentration, T1/2: Half-life, PB: Protein Binding

## DISCUSSION

We describe in this work an updated review of empagliflozin or Jardiance as an albuminuria lowering agent, SGLT2 inhibition, angiotensin receptor blocking and angiotensin converting enzyme inhibition. Research conveyed that in type 2 diabetes patients with; 1) higher baseline HbA1c levels, 2) better renal function, 3) shorter duration of disease, empagliflozin could be considered as a drug of choice associated with glucose-lowering agent [27]. Its' immunotherapy for one and half year was tolerated well with a sensible reduction in HbA1c and weight when compared to placebo [28]. Polypharmacy based on insulin and empagliflozin for four weeks in Japanese participants with type 1 diabetes increased; 1) urinary glucose excretion, 2) improved glycemic control and 3) reduced total daily insulin needs and body weight. There was no indication of hypoglycemia or diabetic ketoacidosis in that population [29].

Visceral adipose tissue is associated with endogenous glycerol-derived hepatic gluconeogenesis and empagliflozin reduces endogenous glycerol-gluconeogenesis in obese adults without type 2 diabetes mellitus. These findings suggest a mechanism by which SGLT2 inhibitors may prevent type 2 diabetes mellitus in obesity [30]. In older patients, the drug reduced risks of cardiovascular mortality, heart failure and renal outcomes [31]. A recent meta-analysis confirmed that empagliflozin has a good effect on the HbA1c level in patients with type 2 diabetes mellitus [32]. The drug reduces lipid metabolism of diabetic nephropathy through AdipoR1/P-AMPK/phosphorylated acetyl-CoA carboxylase pathway and delay diabetic nephropathy progress [33]. Managing empagliflozin for a period of six months in those with type 2 diabetes and fatty liver disease (non-alcoholic) confirmed an improvement of liver steatosis and fibrosis [34]. Polypharmacy with valproate could cause an increase in blood trough concentrations of valproate [35,36]. At the 6-months follow-up of empagliflozin, urinary acetyl-β-D-glucosaminidase excretion was decreased. Renal tubular damage

may be relieved by the prescription of SGLT2 inhibitors through a reduction in the dose of loop diuretics administered and the production of erythropoietin [37-40].

Therefore, this review presents simplicity toward clinical pharmacokinetics aspects' and pharmacotherapy associated with proteinuria, SGLT2, angiotensin receptor and angiotensin converting enzyme.

## CONCLUSION

In summary we updated review of Empagliflozin for treatment of diabetes, overweight and blood pressure, heart failure with or without diabetes and kidney disease. Its' pharmacotherapy could provide short and long term benefit regarding to lowering albuminuria irrespective of its' status. In addition the drug reduces the dose of loop diuretics and increases the production of erythropoietin. It is effective in decreasing HbA1c and reducing body weight. Polypharmacy with valproate needs further vigilance due to increase in blood concentrations of valproate. However it could be recommended for patients with chronic kidney disease but publications suggested that it might not be suitable choice of treatment for those with end stage renal disease.

## REFERENCES

- Matthew J, Levine FACE. Empagliflozin for type 2 Diabetes Mellitus: an overview of phase 3 clinical trials. *Curr Diabetes Rev.* 2017;13(4): 405-423.
- Scheen AJ. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. *Clin Pharmacokinet.* 2014;53(3):213-225.
- Yiling Fu, Davorka Breljak, Akira Onishi, Falk Batz, Rohit Patel, Winnie Huang, et al. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin. *Am J Physiol Renal Physiol.* 2018;315(2):F386-F394..

4. Llorens-Cebrià C, Molina-Van den Bosch M, Vergara A, Jacobs-Cachá C, José Soler M. Antioxidant roles of SGLT2 inhibitors in the kidney. *Biomolecules*. 2022;12(1):143.
5. Lee TI, Chen YC, Lin YK, Chung CC, Lu YY, Kao YH, et al. Empagliflozin attenuates myocardial sodium and calcium dysregulation and reverses cardiac remodeling in Streptozotocin-induced diabetic rats. *Int J Mol Sci*. 2019;20(7):1680.
6. Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J. Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. *Redox Biol*. 2018;15:335–346.
7. Michel MC, Mayoux E, Vallon V. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. *Naunyn Schmiedebergs Arch Pharmacol*. 2015;388(8):801–816.
8. Kusaka H, Koibuchi N, Hasegawa Y, Ogawa H, Kim-Mitsuyama S. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome. *Cardiovasc Diabetol*. 2016;15:157.
9. Liang Xu, Naoto Nagata, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, Guanliang Chen, et al. SGLT2 inhibition by Empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. *E Bio Medicine*. 2017;20:137–149.
10. Hsiang-Chun Lee, Yi-Lin Shiou, Shih-Jie Jhuo, Chia-Yuan Chang, Po-Len Liu, Wun-Jyun Jhuang, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats. *Cardiovasc Diabetol*. 2019;18: 45.
11. Kohei Kaku, Masakazu Haneda, Yuko Tanaka, Ganghyuck Lee, Kosuke Shiki, Yuki Miyamoto, et al. Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial. *Diabetes Obes Metab* 2019;21(1):136–145.
12. Sven Kohler, Cordula Zeller, Hristo Iliev, Stefan Kaspers. Safety and tolerability of Empagliflozin in patients with type 2 diabetes: pooled analysis of phase i-iii clinical trials. *Adv Ther*. 2017;34(7): 1707–1726.
13. Bowen Lin, Nobutaka Koibuchi, Yu Hasegawa, Daisuke Sueta, Kensuke Toyama, Ken Uekawa, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. *Cardiovasc Diabetol*. 2014;13:148.
14. Kwong-Man Ng, Yee-Man Lau, Vidhu Dhandhanian, Zhu-Jun Cai, Yee-Ki Lee, Wing-Hon Lai, et al. Empagliflozin ameliorates high glucose induced-cardiac dysfunction in human iPSC-Derived cardiomyocytes. *Sci Rep* 2018; 8: 14872.
15. Wang M, Wang Z, Chen Y, Dong Y. Kidney damage caused by obesity and its feasible treatment drugs. *Int J Mol Sci*. 2022;23(2): 747.
16. Piero Ruggerenti, Bettina J Kraus, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, et al. Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. *E Clinical Medicine*. 2022;43:101240.
17. Yueh-Ting Lee, Chien-Ning Hsu, Chung-Ming Fu, Shih-Wei Wang, Chiang-Chi Huang, Lung-Chih Li. Comparison of adverse kidney outcomes with Empagliflozin and Linagliptin use in patients with type 2 diabetic patients in a real-world setting. *Front Pharmacol*. 2021;12:781379.
18. Eleni Petra, Justyna Siwy, Antonia Vlahou, Joachim Jankowski. Urine peptidome in combination with transcriptomics analysis highlights MMP7, MMP14 and PCSK5 for further investigation in chronic kidney disease. *PLoS One*. 2022;17(1):0262667.
19. Ryuzo Kawamori, Masakazu Haneda, Keiko Suzaki, Gang Cheng, Kosuke Shiki, Yuki Miyamoto, et al. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial. *Diabetes Obes Metab*. 2018;20(9):2200–2209.
20. Chenguang Li, Jie Zhang, Mei Xue, Xiaoyu Li, Fei Han, Xiangyang Liu, et al. SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. *Cardiovasc Diabetol*. 2019;18:15.
21. Ian J Neeland, Usman Salahuddin, Darren K McGuire. A Safety Evaluation of Empagliflozin for the Treatment of Type 2 Diabetes. *Expert Opin Drug Saf*. 2016;15(3):393–402.
22. Liang Xu, Naoto Nagata, Guanliang Chen, Mayumi Nagashimada, Fen Zhuge, Yinhua Ni, et al. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. *BMJ Open Diabetes Res Care*. 2019;7(1):000783.
23. Masashi Mizuno, Atsushi Kuno, Toshiyuki Yano, Takayuki Miki, Hiroto Oshima, Tatsuya Sato, et al. Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts. *Physiol Rep*. 2018;6(12):13741.
24. Nadjib Hammoudi, Dongtak Jeong, Rajvir Singh, Ahmed Farhat, Michel Komajda, Eric Mayoux, et al. Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. *Cardiovasc Drugs Ther*. 2017;31(3):233–246.
25. Christoph Wanner, Hiddo JL Heerspink, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, et al. Maximilian von Eynatten, Per-Henrik Groop, on behalf of the EMPA-REG OUTCOME Investigators. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. *J Am Soc Nephrol*. 2018;29(11): 2755–2769.
26. Yun-hong Lu, Yun-peng Chang, Ting Li, Fei Han, Chun-jun Li, Xiao-yu Li, et al. Empagliflozin attenuates hyperuricemia by upregulation of ABCG2 via AMPK/AKT/CREB signaling pathway in type 2 diabetic mice. *Int J Biol Sci*. 2020;16(3):529–542.
27. Sam Tsz Wai Cheng, Lihua Chen, Stephen Yu Ting Li, Eric Mayoux, Po Sing Leung. The effects of Empagliflozin, an SGLT2 inhibitor, on pancreatic  $\beta$ -cell mass and glucose homeostasis in type 1 diabetes. *PLoS One*. 2016;11(1):0147391.
28. Naveed Sattar, David Fitchett, Stefan Hantel, Jyothis T. George, Bernard Zinman. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME trial. *Diabetologia*. 2018;61(10):2155–2163.
29. Yun Kyung Cho, Jiwoo Lee, Yu Mi Kang, Jee Hee Yoo, Joong-Yeol Park, Chang Hee Jung, et al. Clinical parameters affecting the therapeutic efficacy of empagliflozin in patients with type 2 diabetes. *PLoS One*. 2019;14(8):0220667.
30. Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, et al. Broedl, On behalf of the EMPA-REG EXTEND™ MONO investigators. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. *Cardiovasc Diabetol* 2015; 14: 154.
31. Akira Shimada, Toshiaki Hanafusa, Atsutaka Yasui, Ganghyuck Lee, Yusuke Taneda, Akiko Sarashina, et al. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial. *Diabetes Obes Metab*. 2018; 20(9): 2190–2199.



32. Ian J Neeland, Natalia de Albuquerque Rocha, Connor Hughes, Colby R Ayers, Craig R. Malloy, Eunsook S Jin. Effects of empagliflozin treatment on glycerol-derived hepatic gluconeogenesis in obese adults: a randomized clinical trial. *Obesity*. 2020;28(7):1254-1262.
33. Pedro Monteiro, Richard M Bergenstal, Elvira Tournal, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, et al. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME trial. *Age Ageing*. 2019;48(6):859-866.
34. Mao-Bing Chen, Hua Wang, Qi-Han Zheng, Hua-Lan Xu, Wei-Yan Cui. Effect of sodium-dependent glucose transporter inhibitors on glycated hemoglobin A1c after 24 weeks in patients with diabetes mellitus: A systematic review and meta-analysis. *Medicine (Baltimore)* 2021;100(1):24101.
35. Zhiqin Zhang, Lihua Ni, Lian Zhang, Dongqing Zha, Chun Hu, Lingli Zhang, et al. Empagliflozin regulates the AdipoR1/p-AMPK/p-ACC pathway to alleviate lipid deposition in diabetic nephropathy. *Diabetes Metab Syndr Obes*. 2021;14:227-240.
36. Chehrehgosha H, Sohrabi MR, Ismail-Beigi F, Malek M, Babaei MR, Zamani F, et al. Empagliflozin improves liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-Controlled clinical trial. *Diabetes Ther*. 2021;12(3):843-861.
37. Miyauchi T. Valproate intoxication in a patient with bipolar I disorder due to SGLT2 inhibitor-induced weight reduction. *Daru*. 2020;28(1):419-421.
38. Caparrotta TM, Greenhalgh AM, Osinski K, Gifford RM, Moser S, Wild SH, et al. Sodium-Glucose Co-Transporter 2 Inhibitors (SGLT2i) exposure and outcomes in type 2 diabetes: a systematic review of population-based observational studies. *Diabetes Ther*. 2021; 12(4): 991-1028.
39. Shirakabe A, Matsushita M, Kiuchi K, Okazaki H, Inami T, Takayasu T, et al. Administration can decrease the dose of loop diuretics and prevent the exacerbation of renal tubular injury in patients with compensated heart failure complicated by diabetes. *Circ Rep*. 2020; 2(10): 565-575.
40. Inzucchi SE, Davies MJ, Khunti K, Trivedi P, George JT, Zwiener I, et al. Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. *Diabetes Obes Metab*. 2021; 23(2): 425-433.